nav-left cat-right
cat-right

CLC bio moves to new Headquarters in Denmark

Aarhus Denmark — July 10, 2008 — On July 1st, CLC bio moved their Danish headquarters to a newly built office building in the Katrinebjerg area – a fast growing Danish ICT community which also features high-tech companies Google, VMware, and B&O, to name a few – as well as the University of Aarhus and the new interdisciplinary nanoscience center, which is currently under construction. CEO at...

Genedata and Axxam Announce High Throughput Screen...

Genedata and Axxam have signed a multi-year contract for the implementation of the Genedata Screener® data analysis and management platform into Axxam’s high throughput screening process. Genedata, the leading provider of in silico solutions for the pharmaceutical and life science industries, and Axxam, a leading biotechnology research organization offering early-stage discovery research services for the life science...

Synthetic Heterocyclic Chemistry

Design Syntheses, Develop Processes 13 – 14 October 2008, London, UK This Synthetic Heterocyclic Chemistry conference is aimed at industrial chemists in discovery chemistry, process R&D and production. The programme contains a mix of industrial and academic presentations, focusing on ‘de novo’ synthesis and partial synthesis of heterocyclic compounds, along with new synthetic methods and case studies...

4th Annual International Conference on Compound Li...

From Focused Compound Libraries to optimised Hit-to-Lead – that’s the motto of IQPC’s 4th international conference on “Compound Libraries” (formerly “Focused Compound Libraries”). Nowadays the pharmaceutical industry is under enormous pressure, and the key for the industry to survive is faster and more efficient drug discovery. To improve their lead generation process and library,...

Galapagos announces milestone payment of EUR 0.8 m...

Galapagos NV (Euronext: GLPG) announced today that it has reached two new milestones in its multi-year drug discovery alliance with GlaxoSmithKline in osteoarthritis, triggering a payment of EUR 0.8 million from GSK. In June 2006, GSK’s Center of Excellence for External Drug Discovery (CEEDD) and Galapagos initiated a program to deliver disease-modifying drugs with clinical Proof of Concept to GSK’s global...

Rentschler Biotechnologie Announces Cooperation wi...

Laupheim, Germany, Mai 21, 2008 – Rentschler Biotechnologie and Boehringer Ingelheim, both leading companies in biopharmaceutical development and production, have signed a preferred partnership agreement. The cooperation will enable Rentschler Biotechnologie’s clients to gain access to Boehringer Ingelheim’s large-scale mammalian biopharmaceutical production facilities in Biberach, Germany and vice ...
Page 30 of 61« First...1020...2829303132...405060...Last »